WASHINGTON, DC (May 14, 2020) — The Association for Accessible Medicines (AAM) has filed an amicus brief in the latest constitutional challenge to the Affordable Care Act (ACA), arguing that even if the individual mandate of the ACA is deemed unconstitutional, the biosimilars pathway (BPCIA) should survive.
“FDA-approved biosimilars offer patients and taxpayers enormous cost savings on life-saving treatments,” said AAM Interim CEO and General Counsel Jeff Francer. “AAM and its members supported the strong bipartisan consensus that led to the passage of the Biologics Price Competition and Innovation Act of 2009 (BPCIA), and we are proud to continue to support this regulatory pathway. If a constitutional challenge to some provisions of the Affordable Care Act (ACA) resulted in the invalidation of the entire ACA, including the BPCIA, a decade of progress by AAM and its members would be lost—and at a crucial moment.”
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.